MARY FIL: Open Payments
NPI 1154915643 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,543 in 85 payments from 15 companies in 2025. Trend: 2023 $1,018 · 2024 $1,077 · 2025 $1,543
Food & beverage: $1,543
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $464 |
| Ardelyx, Inc. | 9 | $177 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $155 |
| Madrigal Pharmaceuticals | 5 | $139 |
| Janssen Biotech, Inc. | 7 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $116 |
| PFIZER INC. | 5 | $81 |
| Aimmune Therapeutics, Inc. | 4 | $68 |
| Ipsen Biopharmaceuticals, Inc | 2 | $58 |
| QOL Medical, LLC | 2 | $49 |
Products named: RINVOQ, IBSRELA, XIFAXAN, REZDIFFRA, TREMFYA, LINZESS, ENTYVIO, XELJANZ.
Industry payments across AL — which companies pay providers there.
